Genmab A/S (NASDAQ:GMAB) Shares Sold by Bank of Montreal Can

Bank of Montreal Can cut its position in shares of Genmab A/S (NASDAQ:GMAB) by 1.5% during the 3rd quarter, Holdings Channel reports. The firm owned 75,819 shares of the company’s stock after selling 1,168 shares during the period. Bank of Montreal Can’s holdings in Genmab A/S were worth $1,845,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of GMAB. DDD Partners LLC acquired a new position in Genmab A/S during the second quarter worth about $8,860,000. Cubist Systematic Strategies LLC boosted its position in shares of Genmab A/S by 109.7% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 278,541 shares of the company’s stock valued at $7,000,000 after purchasing an additional 145,689 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after purchasing an additional 103,859 shares during the last quarter. Sanctuary Advisors LLC acquired a new position in shares of Genmab A/S in the 2nd quarter worth approximately $1,354,000. Finally, Ingalls & Snyder LLC lifted its stake in Genmab A/S by 29.3% during the second quarter. Ingalls & Snyder LLC now owns 229,700 shares of the company’s stock valued at $5,772,000 after purchasing an additional 52,117 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on GMAB. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 target price on shares of Genmab A/S in a report on Wednesday, September 11th. Redburn Atlantic assumed coverage on Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, October 16th. Finally, BMO Capital Markets restated an “outperform” rating and set a $48.00 price objective (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus target price of $45.20.

Genmab A/S Trading Up 0.9 %

Shares of GMAB stock opened at $21.85 on Friday. The company has a market capitalization of $14.46 billion, a price-to-earnings ratio of 21.21, a P/E/G ratio of 0.67 and a beta of 0.96. Genmab A/S has a 1-year low of $20.34 and a 1-year high of $32.88. The stock’s fifty day simple moving average is $22.46 and its 200-day simple moving average is $25.41.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). The business had revenue of $816.10 million for the quarter, compared to analyst estimates of $838.20 million. Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. During the same quarter in the previous year, the business posted $0.47 earnings per share. On average, sell-side analysts predict that Genmab A/S will post 1.3 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.